Treatment of SSNHL in the COVID-19 pandemic – time for changes

Our work aimed to review the literature about sudden sensorineural hearing loss (SSNHL) treatment and the approach to this problem during the COVID-19 pandemic. Current knowledge on SSNHL was sought and presented based on literature published in English-language journals from the Master Journal List. We searched for articles in the MEDLINE, PubMed, and Scopus databases. Sudden sensorineural hearing loss (SSNHL) is a relatively common pathology in otolaryngology. The American Academy of Otolaryngology-Head and Neck Surgery published guidelines for managing SSNHL, specifying systemic and intratympanic (IT) steroid therapy and hyperbaric oxygen therapy (HBOT) as the optional adjunctive treatment. However, due to the COVID-19 pandemic, the standard treatment of SSNHL needed to be verified to identify possible interference of virus infection with pharmacological and hyperbaric therapy. The general use of standard treatment of SSNHL with steroids and HBO according to internationally approved guidelines should ensure safe medical procedures due to epidemiological restrictions. Potential relations between COVID-19 and SSNHL, as well as concomitant use of anticoagulants, should be investigated.